ClinicalTrials.gg
CompletedNCT01984697Updated Aug 8, 2018Results posted

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

A Phase 3 interventional study of V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) in Human Papillomavirus Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 9 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,518
Allocation
Randomized
Ages
9 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Enrollment
10th of 31
1,518 · median 700
Started
2013
the only one that year
Phase 3
16 of 31
2 open now
Registered
4th of 31
by date
Lead sponsor
15 of 31
Merck Sharp & Dohme LLC

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 10th largest by enrollment, is the only one that started in 2013, is one of 16 in phase 3, and was the 4th registered.

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 9 Years to 26 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal was to establish that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that is not inferior to that observed in young women 16 to 26 years of age who received the standard 3-dose regimen of V503 (i.e., the population and dose regimen used to establish V503 efficacy).

03

Conditions studied

  • Human Papillomavirus Infection
04

Who can participate

Ages eligible
9 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

-Judged to be in good physical health on the basis of medical history, physical examination and laboratory results

Boys and Girls 9 to 14 Years:

-Must not have had coitarche and does not plan on becoming sexually active during the vaccination period

Women 16 to 26 Years:

  • Has never had a Papanicolaou (Pap) test or only had normal Pap test results
  • A lifetime history of 0 to 4 male and/or female sexual partners

Exclusion criteria

Exclusion Criteria:

All Participants:

  • Known allergy to any vaccine component
  • History of severe allergic reaction that required medical intervention
  • Thrombocytopenia or any coagulation disorder
  • Females only: participant is pregnant or expecting to donate eggs during day 1 through month 7
  • Currently , or been diagnosed with immunodeficiency
  • Had a splenectomy
  • Receiving or has received immunosuppressive therapies within the last year
  • Received any immunoglobulin product or blood-derived product within 3 months
  • Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,518 participants (actual)

Study arms

  • Experimental
    Girls 9 to 14 Years V503 at Months 0 and 6

    Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.

    Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

  • Experimental
    Boys 9 to 14 Years V503 at Months 0 and 6

    Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.

    Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

  • Experimental
    Girls and Boys 9 to 14 Years V503 at Months 0 and 12

    Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.

    Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

  • Experimental
    Girls 9 to 14 Years V503 at Months 0, 2, and 6

    Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.

    Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

  • Active comparator
    Young Women 16 to 26 Years V503 at Months 0, 2, and 6

    Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.

    Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  2. Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  3. Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  4. Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  5. Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  6. Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  7. Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  8. Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  9. Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Secondary outcomes

  1. Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer \>=30 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  2. Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer \>=16 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  3. Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer \>=20 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  4. Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer \>=24 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  5. Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer \>=10 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  6. Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer \>=8 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  7. Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer \>=8 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  8. Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer \>=8 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

  9. Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen

    Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer \>=8 mMU/mL.

    Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Other outcomes

  1. Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24

    Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: Month 24

  2. Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24

    Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.

    Time frame: Month 24

  3. Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36

    Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

    Time frame: Month 36

  4. Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36

    Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.

    Time frame: Month 36

07

Results

Posted Apr 26, 2016

Participant flow

Participant flow — Overall Study
MilestoneGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Started301301301301314
Vaccination 1301301300300314
Vaccination 2293296291298313
Vaccination 3000293311
Month 36 vaccination270281280931
Completed258270272280279
Not completed4331292135
Withdrew: Adverse event00200
Withdrew: Lost to follow-up14510621
Withdrew: Physician decision30010
Withdrew: Protocol violation85320
Withdrew: Withdrawal by subject1521131113
Withdrew: Missed last follow-up visit10000
Withdrew: Death00010
Withdrew: Pregnancy20101

Outcome measures

PrimaryGeometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen1657.9 (1479.6 to 1857.6)1557.4 (1391.5 to 1743.1)2678.8 (2390.2 to 3002.1)1496.1 (1334.1 to 1677.8)770.9 (684.8 to 867.9)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.15 · 95% CI 1.83 to 2.53One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.02 · 95% CI 1.73 to 2.36One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 3.47 · 95% CI 2.93 to 4.11One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer \>=30 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 (97.9 to 100)100 (98.6 to 100)100 (98.6 to 100)99.2 (97.2 to 99.9)99.6 (97.7 to 100)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.0 · 95% CI -1.8 to 2.0One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.3One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.1 to 2.3One-sided non-inferiority test at alpha=0.025 level
PrimaryGeometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen1388.9 (1240.4 to 1555.3)1423.9 (1273.2 to 1592.3)2941.8 (2626.6 to 3294.9)1306.3 (1165.5 to 1464.0)580.5 (516.0 to 653.0)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.39 · 95% CI 2.03 to 2.82One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.45 · 95% CI 2.09 to 2.88One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 5.07 · 95% CI 4.32 to 5.94One-sided non-inferiority test at alpha=0.025 level
PrimaryGeometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen8004.9 (7160.5 to 8948.8)8474.8 (7582.4 to 9472.3)14329.3 (12796.4 to 16045.9)6996.0 (6254.1 to 7825.8)3154.0 (2807.1 to 3543.7)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.54 · 95% CI 2.14 to 3.00One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.69 · 95% CI 2.29 to 3.15One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 4.54 · 95% CI 3.84 to 5.37One-sided non-inferiority test at alpha=0.025 level
PrimaryGeometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen1872.8 (1651.6 to 2123.6)1860.9 (1641.1 to 2110.2)2810.4 (2474.9 to 3191.3)2049.3 (1806.4 to 2324.8)761.5 (670.8 to 864.5)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.46 · 95% CI 2.05 to 2.96One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.44 · 95% CI 2.04 to 2.92One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 3.69 · 95% CI 3.06 to 4.45One-sided non-inferiority test at alpha=0.025 level
PrimaryGeometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen1436.3 (1272.1 to 1621.8)1498.2 (1326.5 to 1692.0)2117.5 (1873.7 to 2393.1)1748.3 (1548.1 to 1974.5)572.1 (505.8 to 647.2)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.51 · 95% CI 2.10 to 3.00One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.62 · 95% CI 2.20 to 3.12One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 3.70 · 95% CI 3.08 to 4.45One-sided non-inferiority test at alpha=0.025 level
PrimaryGeometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen1030.0 (920.4 to 1152.7)1040.0 (928.9 to 1164.3)2197.5 (1961.9 to 2461.3)796.4 (712.0 to 890.9)348.1 (311.5 to 389.1)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.96 · 95% CI 2.50 to 3.50One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.99 · 95% CI 2.55 to 3.50One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 6.31 · 95% CI 5.36 to 7.43One-sided non-inferiority test at alpha=0.025 level
PrimaryGeometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen357.6 (313.7 to 407.6)352.3 (309.0 to 401.7)417.7 (365.9 to 476.9)661.7 (580.6 to 754.1)213.6 (187.7 to 243.2)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 1.67 · 95% CI 1.38 to 2.03One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 1.65 · 95% CI 1.37 to 1.99One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 1.96 · 95% CI 1.61 to 2.37One-sided non-inferiority test at alpha=0.025 level
PrimaryGeometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen581.1 (521.9 to 647.1)640.4 (575.2 to 713.0)1123.4 (1008.1 to 1251.9)909.9 (817.6 to 1012.5)364.2 (327.0 to 405.6)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 1.60 · 95% CI 1.36 to 1.87One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 1.76 · 95% CI 1.51 to 2.05One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 3.08 · 95% CI 2.64 to 3.61One-sided non-inferiority test at alpha=0.025 level
PrimaryGeometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen1251.2 (1119.6 to 1398.4)1325.7 (1186.2 to 1481.6)2444.6 (2185.2 to 2734.9)1229.3 (1100.7 to 1373.0)491.1 (438.6 to 549.8)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.55 · 95% CI 2.15 to 3.01One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 2.70 · 95% CI 2.30 to 3.16One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · ANOVA · p = <0.001 · Gmt ratio: 4.98 · 95% CI 4.23 to 5.86One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer \>=16 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 (98.6 to 100)100 (98.6 to 100)100 (98.6 to 100)99.6 (97.8 to 100)99.6 (97.7 to 100)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.1 to 2.3One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.3One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.1 to 2.3One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer \>=20 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 (98.7 to 100)100 (98.7 to 100)100 (98.6 to 100)100 (98.6 to 100)99.6 (97.8 to 100)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.2One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.2One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.2One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer \>=24 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 (98.7 to 100)100 (98.7 to 100)100 (98.6 to 100)99.6 (98.0 to 100)98.5 (96.2 to 99.6)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 1.5 · 95% CI 0.1 to 3.8One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 1.5 · 95% CI 0.1 to 3.8One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 1.5 · 95% CI 0.1 to 3.8One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer \>=10 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 (98.0 to 100)100 (98.6 to 100)100 (98.6 to 100)100 (98.6 to 100)99.6 (97.9 to 100)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.0 · 95% CI -1.7 to 1.8One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.1One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.1One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer \>=8 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 (98.0 to 100)100 (98.6 to 100)100 (98.6 to 100)100 (98.7 to 100)99.6 (98.0 to 100)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.0 · 95% CI -1.7 to 1.7One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.0One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.1 to 2.0One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer \>=8 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.3 (97.4 to 99.9)99.3 (97.4 to 99.9)100 (98.6 to 100)99.3 (97.4 to 99.9)97.9 (95.4 to 99.2)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 1.4 · 95% CI -0.7 to 4.0One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 1.4 · 95% CI -0.7 to 4.0One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 2.1 · 95% CI 0.7 to 4.6One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer \>=8 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 (98.0 to 100)100 (98.7 to 100)100 (98.6 to 100)99.6 (98.0 to 100)99.6 (98.0 to 100)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.0 · 95% CI -1.7 to 1.7One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.1One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.1One-sided non-inferiority test at alpha=0.025 level
SecondaryPercentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer \>=8 mMU/mL.

Time frame:
4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 (98.6 to 100)100 (98.6 to 100)100 (98.6 to 100)99.6 (98.0 to 100)99.6 (97.9 to 100)
Statistical analysis
  • Girls 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.1One-sided non-inferiority test at alpha=0.025 level
  • Boys 9 to 14 Years V503 at Months 0 and 6 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.0 to 2.1One-sided non-inferiority test at alpha=0.025 level
  • Girls and Boys 9 to 14 Years V503 at Months 0 and 12 vs Young Women 16 to 26 Years V503 at Months 0, 2, and 6 · Miettinen and Nurminen · p = <0.001 · Seroconversion percentage difference: 0.4 · 95% CI -1.1 to 2.1One-sided non-inferiority test at alpha=0.025 level
Other pre-specifiedAntibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24

Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
Month 24
Reported as:
Geometric mean · mMU/mL
Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Anti-HPV Type 6260.7 (231.5 to 293.6)209.1 (185.9 to 235.1)574.0 (509.6 to 646.5)300.7 (266.8 to 339.0)153.2 (135.4 to 173.5)
Anti-HPV Type 11169.8 (150.5 to 191.7)150.6 (133.6 to 169.7)443.7 (392.9 to 501.0)201.9 (178.7 to 228.1)98.3 (86.6 to 111.6)
Anti-HPV Type 16900.5 (788.0 to 1028.9)801.0 (701.5 to 914.6)2316.2 (2023.5 to 2651.4)1041.3 (910.8 to 1190.4)461.6 (401.2 to 531.0)
Anti-HPV Type 18196.8 (174.9 to 221.6)169.6 (150.7 to 190.8)380.8 (337.9 to 429.1)255.8 (227.2 to 288.0)122.2 (108.4 to 137.7)
Anti-HPV Type 31160.6 (140.8 to 183.3)139.1 (122.0 to 158.7)312.8 (273.9 to 357.1)260.6 (228.4 to 297.3)89.6 (78.4 to 102.5)
Anti-HPV Type 33131.2 (116.9 to 147.2)121.5 (108.3 to 136.4)341.7 (304.3 to 383.6)120.8 (107.7 to 135.4)61.3 (54.6 to 68.7)
Anti-HPV Type 4537.8 (33.2 to 43.0)31.9 (28.0 to 36.3)62.3 (54.7 to 71.1)86.9 (76.4 to 98.9)30.7 (27.0 to 34.9)
Anti-HPV Type 5285.1 (76.4 to 94.7)80.9 (72.7 to 90.0)199.4 (179.0 to 222.2)150.4 (135.2 to 167.4)73.7 (66.1 to 82.1)
Anti-HPV Type 58155.4 (138.0 to 175.1)149.8 (133.1 to 168.6)380.2 (337.3 to 428.6)183.7 (163.3 to 206.7)76.8 (68.0 to 86.7)
Other pre-specifiedAntibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24

Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.

Time frame:
Month 24
Reported as:
Number · Percentage of participants
Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Anti-HPV Type 698.4 (96.0 to 99.6)96.9 (94.0 to 98.7)99.2 (97.2 to 99.9)99.6 (97.8 to 100)94.0 (90.1 to 96.7)
Anti-HPV Type 1198.0 (95.4 to 99.4)95.8 (92.6 to 97.9)99.6 (97.8 to 100)98.8 (96.5 to 99.8)94.8 (91.1 to 97.3)
Anti-HPV Type 1698.9 (96.7 to 99.8)99.6 (97.9 to 100)100 (98.6 to 100)99.6 (97.9 to 100)99.6 (97.7 to 100)
Anti-HPV Type 1898.5 (96.2 to 99.6)95.9 (92.8 to 97.9)98.9 (96.7 to 99.8)99.2 (97.3 to 99.9)95.0 (91.6 to 97.3)
Anti-HPV Type 3197.0 (94.2 to 98.7)94.8 (91.4 to 97.1)98.5 (96.2 to 99.6)97.7 (95.2 to 99.2)91.5 (87.4 to 94.6)
Anti-HPV Type 3397.8 (95.2 to 99.2)96.6 (93.7 to 98.4)99.2 (97.3 to 99.9)98.9 (96.8 to 99.8)94.8 (91.4 to 97.1)
Anti-HPV Type 4588.4 (84.0 to 92.0)85.9 (81.1 to 89.8)93.9 (90.3 to 96.5)96.7 (93.8 to 98.5)82.7 (77.6 to 87.0)
Anti-HPV Type 5296.6 (93.7 to 98.4)95.2 (91.9 to 97.4)99.2 (97.3 to 99.9)99.3 (97.3 to 99.9)97.3 (94.6 to 98.9)
Anti-HPV Type 5898.9 (96.7 to 99.8)99.6 (97.9 to 100)100 (98.6 to 100)100 (98.6 to 100)96.0 (92.9 to 98.1)
Other pre-specifiedAntibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36

Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame:
Month 36
Reported as:
Geometric mean · mMU/mL
Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36
mMU/mLGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Anti-HPV Type 6209.6 (184.9 to 237.6)160.1 (141.9 to 180.7)401.2 (354.8 to 453.7)232.2 (205.1 to 263.0)133.8 (117.3 to 152.7)
Anti-HPV Type 11133.7 (117.6 to 152.1)115.2 (101.8 to 130.3)308.2 (271.8 to 349.6)159.1 (140.0 to 180.7)82.9 (72.4 to 94.9)
Anti-HPV Type 16673.8 (582.8 to 779.1)592.6 (514.7 to 682.4)1534.3 (1328.8 to 1771.5)792.4 (686.7 to 914.4)368.9 (316.4 to 430.0)
Anti-HPV Type 18158.9 (140.8 to 179.4)141.7 (125.9 to 159.4)276.4 (245.3 to 311.6)206.5 (183.3 to 232.7)104.1 (92.0 to 117.8)
Anti-HPV Type 31127.8 (111.4 to 146.5)106.9 (93.5 to 122.1)218.0 (190.6 to 249.4)205.9 (180.0 to 235.5)74.6 (64.8 to 85.9)
Anti-HPV Type 33106.0 (94.1 to 119.5)95.7 (85.1 to 107.5)240.4 (213.8 to 270.3)95.5 (85.0 to 107.3)52.2 (46.3 to 58.9)
Anti-HPV Type 4530.6 (26.9 to 35.0)26.8 (23.6 to 30.4)43.6 (38.3 to 49.7)66.1 (58.1 to 75.2)27.3 (23.9 to 31.1)
Anti-HPV Type 5266.2 (59.1 to 74.0)63.4 (56.8 to 70.7)143.2 (128.3 to 159.9)115.9 (103.9 to 129.3)61.5 (54.8 to 68.9)
Anti-HPV Type 58125.8 (111.1 to 142.5)119.2 (105.6 to 134.5)265.3 (234.8 to 299.8)143.0 (126.7 to 161.5)64.7 (56.9 to 73.6)
Other pre-specifiedAntibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36

Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.

Time frame:
Month 36
Reported as:
Number · Percentage of participants
Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36
Percentage of participantsGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Anti-HPV Type 695.3 (91.8 to 97.7)91.3 (87.2 to 94.5)99.2 (97.1 to 99.9)97.9 (95.2 to 99.3)92.1 (87.6 to 95.3)
Anti-HPV Type 1194.1 (90.2 to 96.7)92.9 (89.1 to 95.8)99.2 (97.1 to 99.9)98.8 (96.4 to 99.7)92.1 (87.6 to 95.3)
Anti-HPV Type 1697.2 (94.3 to 98.9)98.5 (96.2 to 99.6)100 (98.6 to 100)99.2 (97.2 to 99.9)98.2 (95.5 to 99.5)
Anti-HPV Type 1895.6 (92.2 to 97.8)94.3 (90.7 to 96.8)97.6 (94.9 to 99.1)97.3 (94.4 to 98.9)90.8 (86.4 to 94.1)
Anti-HPV Type 3194.0 (90.2 to 96.6)91.2 (87.1 to 94.3)96.5 (93.5 to 98.4)97.7 (95.0 to 99.1)86.0 (80.8 to 90.1)
Anti-HPV Type 3394.0 (90.3 to 96.6)96.9 (94.1 to 98.7)99.2 (97.2 to 99.9)98.1 (95.6 to 99.4)91.9 (87.7 to 95.0)
Anti-HPV Type 4583.6 (78.4 to 88.0)81.4 (76.1 to 85.9)87.9 (83.3 to 91.7)91.2 (87.1 to 94.3)77.8 (72.1 to 82.8)
Anti-HPV Type 5293.5 (89.7 to 96.3)93.9 (90.3 to 96.5)98.8 (96.6 to 99.8)97.7 (95.1 to 99.2)95.0 (91.4 to 97.4)
Anti-HPV Type 5898.0 (95.3 to 99.3)99.2 (97.3 to 99.9)100 (98.6 to 100)98.8 (96.7 to 99.8)94.8 (91.1 to 97.3)

Adverse events

Collected over Serious Adverse Events: Up to Month 37; Non-injection site adverse events: up to Day 15 following any vaccination; Injection site adverse events: up to Day 5 following any vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Girls 9 to 14 Years V503 at Months 0 and 60/294 (0%)6/294 (2%)53/294 (18%)
Boys 9 to 14 Years V503 at Months 0 and 60/296 (0%)9/296 (3%)32/296 (10.8%)
Girls and Boys 9 to 14 Years V503 at Months 0 and 120/293 (0%)6/293 (2%)46/293 (15.7%)
Girls 9 to 14 Years V503 at Months 0, 2, and 61/300 (0.3%)6/300 (2%)55/300 (18.3%)
Young Women 16 to 26 Years V503 at Months 0, 2, and 60/313 (0%)11/313 (3.5%)90/313 (28.8%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Abortion inducedSurgical and medical procedures0/2940/2960/2930/3004/313
Abdominal painGastrointestinal disorders2/2940/2960/2930/3001/313
AppendicitisInfections and infestations1/2941/2961/2931/3000/313
Forearm fractureInjury, poisoning and procedural complications0/2940/2961/2930/3000/313
Dermatitis atopicSkin and subcutaneous tissue disorders0/2940/2961/2930/3000/313
GastritisGastrointestinal disorders0/2940/2961/2930/3000/313
Oral herpesInfections and infestations0/2940/2961/2930/3000/313
RadiculopathyNervous system disorders0/2940/2961/2930/3000/313
Dengue feverInfections and infestations1/2940/2960/2930/3000/313
PharyngitisInfections and infestations1/2940/2960/2930/3000/313
Most frequent other events
Most frequent other events
EventGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Injection site painGeneral disorders49/29428/29641/29353/30080/313
HeadacheNervous system disorders8/2949/2967/2937/30016/313

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Girls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6Total
Mean11.4 ± 1.711.5 ± 1.711.4 ± 1.611.4 ± 1.721.0 ± 2.713.4 ± 4.3
Age, Customized
Age, Customized(Participants)Girls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6Total
Between 9 and 10 years100981001010399
Between 11 and 12 years1021021061000410
Between 13 and 14 years99101951000395
Between 16 and 26 years0000314314
Sex: Female, Male
Sex: Female, Male(Participants)Girls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6Total
Female30101513013141067
Male030115000451
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, Dvorak V, Kim KH, Cestero RM, Berkovitch M, Ceyhan M, Ellison MC, Ritter MA, Yuan SS, DiNubile MJ, Saah AJ, Luxembourg A. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016 Dec 13;316(22):2411-2421. doi: 10.1001/jama.2016.17615. PubMed 27893068 ↗
  • Bornstein J, Roux S, Kjeld Petersen L, Huang LM, Dobson SR, Pitisuttithum P, Diez-Domingo J, Schilling A, Ariffin H, Tytus R, Rupp R, Senders S, Engel E, Ferris D, Kim YJ, Tae Kim Y, Kurugol Z, Bautista O, Nolan KM, Sankaranarayanan S, Saah A, Luxembourg A. Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine. Pediatrics. 2021 Jan;147(1):e20194035. doi: 10.1542/peds.2019-4035. Epub 2020 Dec 22. PubMed 33386332 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Jun 2015, 18 months.

Results were first posted in Apr 2016, 10 months after primary completion.

Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 18 months is below that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2013
First posted
Nov 15, 2013
StartActual
Dec 12, 2013
Primary completionActual
Jun 19, 2015
CompletionActual
Jul 24, 2017
Results first posted
Apr 26, 2016
Last update
Aug 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01984697
Responsible party
Sponsor
First posted
Nov 15, 2013
Start date
Dec 12, 2013
Primary completion
Jun 19, 2015
Completion
Jul 24, 2017
Results posted
Apr 26, 2016
Last update
Aug 8, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion